Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
523 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 523 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and… | Phase 1 / Phase 2 | terminated | Dec 20, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04807478 | Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis… | — | withdrawn | Mar 19, 2021 | Fresenius Kabi | New study protocol under development | Other (stated, no rule matched) |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With… | Phase 2 | withdrawn | Dec 11, 2020 | Academic and Community Cancer Research United | Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected… | COVID-19 / pandemic |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in… | Phase 2 | terminated | Jul 2, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic… | Phase 1 | withdrawn | Dec 7, 2018 | Baylor College of Medicine | We decided to move on to another product and as a result will not be moving forward with this study. | Other (stated, no rule matched) |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for…(VZCLLPI0146) | Phase 2 | terminated | Nov 16, 2010 | Hackensack Meridian Health | The study was closed early due to poor accrual | Enrollment / accrual |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity…(CD3/CD19 Haplo) | Phase 2 | terminated | Aug 18, 2009 | University Hospital Tuebingen | slow recruitment | Enrollment / accrual |
| NCT01982175 | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia(CLL004) | Phase 2 | suspended | Nov 13, 2013 | Shanghai Zhangjiang Biotechnology Limited Company | recruiting difficulties | Enrollment / accrual |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation…(HATCY) | Phase 3 | terminated | Dec 21, 2016 | Kiadis Pharma | Insufficient efficacy, terminated by Sponsor | Efficacy / futility |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | Phase 1 | terminated | Dec 7, 2012 | TG Therapeutics, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic… | Phase 2 | terminated | Jan 23, 2014 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | Phase 2 | terminated | Aug 31, 2009 | Wake Forest University Health Sciences | Sponsor/ PI leaving institution, no plans to continue this research at this time | Other (stated, no rule matched) |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic… | Phase 2 | terminated | Nov 7, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT04660045 | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Phase 2 | withdrawn | Dec 9, 2020 | Weill Medical College of Cornell University | Company supplying drug/funding ceased support. | Funding |
| NCT01187810 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | Phase 1 | terminated | Aug 24, 2010 | South Plains Oncology Consortium | drug supply | Drug supply |
| NCT03668392 | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic…(ALL2518) | Phase 2 | terminated | Sep 12, 2018 | Gruppo Italiano Malattie EMatologiche dell'Adulto | low enrollment rate | Enrollment / accrual |
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | Phase 1 | terminated | Oct 4, 2018 | Naoyuki G. Saito, M.D., Ph.D. | Extreme toxicity | Safety / toxicity |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | terminated | Dec 24, 2019 | National Heart, Lung, and Blood Institute (NHLBI) | Due to unexpected sudden death on study. | Other (stated, no rule matched) |
| NCT04448834 | Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | Phase 2 | withdrawn | Jun 26, 2020 | Dorothy Sipkins, MD, PhD | Study not moving forward | Other (stated, no rule matched) |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | Phase 2 | terminated | Aug 5, 2019 | University of British Columbia | Slow enrolment, loss of funding | Enrollment / accrual |
| NCT04160195 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for… | Phase 1 | terminated | Nov 12, 2019 | National Cancer Institute (NCI) | The original principal investigator left the National Institutes of Health (NCI) and the decision… | Investigator |
| NCT03851081 | Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed… | Phase 1 / Phase 2 | withdrawn | Feb 22, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT00792831 | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed… | Phase 2 | terminated | Nov 18, 2008 | Italfarmaco | Protocol needs complete restructuring in order to make it feasible and to complete the enrollment… | Enrollment / accrual |
| NCT03153514 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's…(CLLTX1) | Phase 2 | terminated | May 15, 2017 | German CLL Study Group | Prematurely terminated due to poor accrual | Enrollment / accrual |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With… | Phase 1 | terminated | May 9, 2018 | University of Southern California | Study drug supply issue | Drug supply |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute… | Phase 1 / Phase 2 | terminated | Jun 10, 2016 | OncoTherapy Science, Inc. | slow patient accrual | Enrollment / accrual |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | Phase 1 | withdrawn | Aug 21, 2018 | Virginia Commonwealth University | Slow Accrual | Enrollment / accrual |
| NCT03943342 | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After… | Phase 2 | withdrawn | May 9, 2019 | Kerry Rogers | Study not feasible | Other (stated, no rule matched) |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic… | Phase 2 | terminated | Jun 15, 2012 | OHSU Knight Cancer Institute | Unable to recruit enough eligible subjects | Enrollment / accrual |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | Phase 1 / Phase 2 | terminated | Apr 26, 2012 | Gilead Sciences | Study was terminated due to lack of efficacy, as a result, the stability program for the drug… | Efficacy / futility |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT01439347 | A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With… | Phase 3 | terminated | Sep 23, 2011 | Spectrum Pharmaceuticals, Inc | Sponsor decision | Sponsor / business decision |
| NCT03742323 | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | terminated | Nov 15, 2018 | PETHEMA Foundation | Because of low recruitment | Enrollment / accrual |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | Phase 1 | terminated | Nov 19, 2012 | Gilead Sciences | Study was stopped due to insufficient efficacy and very slow accrual | Efficacy / futility |
| NCT02928510 | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic… | — | terminated | Oct 10, 2016 | Jonsson Comprehensive Cancer Center | withdrawn by sponsor | Other (stated, no rule matched) |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | Phase 1 | terminated | Jul 9, 2018 | M.D. Anderson Cancer Center | Study halted prematurely | Other (stated, no rule matched) |
| NCT02669264 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute… | Phase 1 | terminated | Feb 1, 2016 | ADC Therapeutics S.A. | The study was early terminated prior to part 2 because of slow accrual. | Enrollment / accrual |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | Phase 1 | terminated | Jul 19, 2012 | Aptevo Therapeutics | Business decision | Sponsor / business decision |
| NCT02341209 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL) | Phase 2 | terminated | Jan 19, 2015 | Rochester General Hospital | Low enrollment | Enrollment / accrual |
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD… | Phase 3 | withdrawn | Feb 28, 2017 | Loyola University | No participants were enrolled | Enrollment / accrual |
| NCT01685411 | Busulfan and Cyclophosphamide Followed By ALLO BMT | N/A | terminated | Sep 14, 2012 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT03094611 | Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive… | Phase 2 | terminated | Mar 29, 2017 | M.D. Anderson Cancer Center | the study was closed early due to competing trials | Other (stated, no rule matched) |
| NCT02336048 | A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care… | Phase 1 | terminated | Jan 12, 2015 | Hoffmann-La Roche | This study was terminated early because premedication with tocilizumab was unlikely to reduce the… | Other (stated, no rule matched) |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT00439296 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | Phase 1 / Phase 2 | terminated | Feb 23, 2007 | Therapeutic Advances in Childhood Leukemia Consortium | The study was stopped due to poor accrual and lack of funding. | Enrollment / accrual |
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of…(REAL) | — | terminated | Apr 10, 2020 | SecuraBio | Strategy Change | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 22, 2022source: clinicaltrials